The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Gail Roboz | ASH 2018 | Key highlights of IDH inhibitors at ASH 2018

Dec 10, 2018

Gail Robozfrom the Weill Cornell Medicine, New York, US discusses of the use and advancement of IDH inhibitors in patients with IDH1 and IDH2 mutated acute myeloid leukemia (AML) at the 60 thAmerican Society Hematology Annual Meeting

Key highlights of IDH inhibitors at ASH 2018